Diabetes and CKD in the United States population, 2009-2014
Open accessAbstract
Background and objectives Diabetes is an important cause of CKD. However, among people with diabetes, it is unclear to what extent CKD is attributable to diabetes itself versus comorbid conditions, such as advanced age and hypertension. We examined associations of diabetes with clinical manifestations of CKD independent of age and BP and the extent to which diabetes contributes to the overall prevalence of CKD in the United States. Design, setting, participants, & measurements We performed a cross-sectional study of 15,675 participants in the National Health and Nutrition Examination Surveys from 2009 to 2014. Diabetes was defined by use of glucose-lowering medications or hemoglobin A 1c ≥6.5%. eGFR was calculated using the CKD Epidemiology Collaboration formula, and albumin-to-creatinine ratio was measured in single-void urine samples. We calculated the prevalence of CKD manifestations by diabetes status as well as prevalence ratios, differences in prevalence, and prevalence attributable to diabetes using binomial and linear regression, incorporating data from repeat eGFR and urine albumin-to-creatinine ratio measurements to estimate persistent disease. Results For participants with diabetes ( n =2279) versus those without diabetes ( n =13,396), the estimated prevalence of any CKD (eGFR 2 ; albumin-to-creatinine ratio ≥30 mg/g, or both) was 25% versus 5.3%, respectively; albumin-to-creatinine ratio ≥30 mg/g was 16% versus 3.0%, respectively; albumin-to-creatinine ratio ≥300…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
People with T2D and lower levels of albuminuria (ACR 30-299 mg/g) represent a larger proportion of people with T2D with increased CVD risk but at lower risk of CKD progression.
“This recommendation also applies to people with T2D and lower levels of albuminuria (ACR 30 -299 mg/g [3 -29.9 mg/mmol]), which represent a larger proportion of people with T2D with increased CVD risk but at lower risk of CKDprogression.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [176]
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603 · see citing works
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · see citing works
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401 · see citing works
Diabetic kidney disease: a report from an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1296 · Cited by 1,153 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373 · see citing works
Self-citationLee, M.-R., Jung, S. M., Bang, H., Kim, H. S., & Kim, Y. B. (2018) · Medicine · doi:10.1097/md.0000000000010984 · Cited by 95 · see citing works
Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes
Limonte, C. P., Hall, Y. N., Trikudanathan, S., Tuttle, K. R., Hirsch, I. B., de Boer, I. H., & Zelnick, L. R. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108204 · Cited by 58 · see citing works
Self-citationChen, L., Zhang, Y., Li, C., Li, Q., & He, L. (2023) · Nursing Open · doi:10.1002/nop2.1349 · Cited by 28 · see citing works
“From 2013– 2016, the prevalence rate of CKD in the United States was 14.8% (Zelnick et al., 2017), and in China, its prevalence has been increasing (Yang et al., 2021).”
BackgroundInfluential
- Authors
- Zelnick, L. R., Weiss, N. S., Kestenbaum, B. R., Robinson-Cohen, C., Heagerty, P. J., Tuttle, K., Hall, Y. N., Hirsch, I. B., & de Boer, I. H.
- Affiliations
- Kidney Research Institute, Division of Nephrology, and
- Epidemiology and
- Biostatistics, and
- University of Washington (US)
- Group Health Cooperative (US)
- Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine,
- Corresponding author
- Zelnick, Leila R.
- Kestenbaum, Bryan R.
- Tuttle, Katherine
- Hirsch, Irl B.
- ORCID
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2017-10-20
- Volume
- 12
- Issue
- 12
- Pages
- 1984-1990
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC5718269
- OpenAlex
- W2765189203
- Cited by
- 181
- References
- 4
- Citations by year
- 2026: 16 · 2025: 26 · 2024: 21 · 2023: 11 · 2022: 30 · 2021: 22 · 2020: 31 · 2019: 15 · 2018: 8 · 2017: 1
- FWCI
- 13.46
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- American Society of Nephrology
- Northwest Kidney Centers
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK088762)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetes mellitus, chronic kidney disease, CKD prevalence, albumin-creatinine ratio, estimated glomerular filtration rate, hypertension, comorbidities, albuminuria, NHANES, United States population, age adjustment, sex differences, racial and ethnic disparities, socioeconomic status, health insurance status
- MeSH terms
- Albuminuria, Creatinine, Cross-Sectional Studies, Diabetes Mellitus, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Nutrition Surveys, United States, Prevalence, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review